Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00964236 · ClinicalTrials.gov registry record
The Effects of Kuvan on Functional Brain Connectivity in Individuals With Phenylketonuria (PKU)
A clinical trial, sponsored by University of Missouri-Columbia.
- Completed
- Registry status
- 20
- Enrollment target
NCT00964236 is a clinical trial that has completed, run by University of Missouri-Columbia. The registered enrollment target is 20 participants.
The verdict
NCT00964236 has completed, sponsored by University of Missouri-Columbia.
- COMPLETED
- Registry status
- 20 participants
- Enrollment target
Study Summary
The objective of the study is to determine whether Kuvan™ (sapropterin) improves the strength of the functional connectivity between brain regions in individuals with PKU.
Interventions
- DRUG Sapropterin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2009-08 |
| Est. Completion | 2011-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00964236
The ClinicalTrials.gov registry entry for NCT00964236 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Missouri-Columbia, which has 291 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sapropterin is the first listed.
NCT00964236 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00964236 about?
NCT00964236 is a clinical study titled "The Effects of Kuvan on Functional Brain Connectivity in Individuals With Phenylketonuria (PKU)". The objective of the study is to determine whether Kuvan™ (sapropterin) improves the strength of the functional connectivity between brain regions in individuals with PKU.
What is the current status of trial NCT00964236?
This trial is currently completed. The enrollment target is 20 participants. The study started on 2009-08. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00964236?
The interventions under investigation include: Sapropterin (DRUG).
Who is sponsoring clinical trial NCT00964236?
This trial is sponsored by University of Missouri-Columbia, which has 291 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.